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First, we acknowledge the weaknesses of the retrospective design as discussed in the limitations section of our article. 2 In accordance with the European Society of Cardiology guidelines, we included new-onset atrial fibrillation (NOAF) episodes lasting at least 30 seconds. 3 New-onset atrial fibrillation was classified as early-AF when its onset and termination occurred within first 24 hours of admission, hence it was relatively short as well.
Second, undiagnosed, paroxysmal, and especially silent AF are an inherent and universal limitation of studies investigating NOAF. Regarding the possibility of NOAF occurring before hospital admission, we excluded patients with prolonged symptoms prior to presentation (>24 hour) in order to maintain the early-AF group, truly "early."
Third, preliminary findings show that about one-third of early-AF and one half of late-AF underwent an in-hospital cardioversion attempt (electrical or pharmacologic).
Finally, in agreement with Celebi et al, 1 we believe that additional interesting and potentially important parameters should be obtained, analyzed as potential predictors and compared between the 2 subgroups of NOAF to improve prediction and differentiation of these apparently 2 separate clinical entities and improve patient care.
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